Cochrane · systematic review · CD013432
Anti‐IL‐5 therapies for chronic obstructive pulmonary disease
Donovan, T, Milan, SJ, Wang, R, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
40
current version
GRADE rated
40
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 12.5%Moderate 29 · 72.5%High 6 · 15%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Mepolizumab 100 mg compared with placebo for chronic obstructive pulmonary disease
Population: individuals with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rate of moderate or severe exacerbations Eosinophilic phenotype Mepolizumab 100 mg vs placebo | Rate ratio 0.81 [0.71, 0.93] | 2 studies · 911 participants | High |
Rate of moderate or severe exacerbations All participants Mepolizumab 100 mg vs placebo | Rate ratio 0.92 [0.82, 1.03] | 2 studies · 1285 participants | Moderate Downgraded: imprecision, inconsistency |
Time to first moderate or severe exacerbation Eosinophilic phenotype Mepolizumab 100 mg vs placebo | Hazard ratio 0.78 [0.66, 0.92] | 2 studies · 981 participants | High |
Time to first moderate or severe exacerbation All participants Mepolizumab 100 mg vs placebo | Hazard ratio 0.87 [0.75, 1] | 2 studies · 1285 participants | Moderate Downgraded: imprecision, inconsistency |
Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype Mepolizumab 100 mg vs placebo | Rate ratio 0.9 [0.65, 1.24] | 2 studies · 911 participants | Moderate Downgraded: imprecision, inconsistency |
Rate of exacerbations with ED visit or hospitalisations All participants Mepolizumab 100 mg vs placebo | Rate ratio 0.94 [0.72, 1.22] | 2 studies · 1285 participants | Moderate Downgraded: imprecision, inconsistency |
Serious adverse events Mepolizumab 100 mg vs placebo | Odds ratio 0.82 [0.65, 1.05] | 2 studies · 1285 participants | Moderate Downgraded: imprecision |
Health‐related quality of life: change in SGRQ total score Scale: 0 to 100 (lower is better) Eosinophilic phenotype Mepolizumab 100 mg vs placebo | no estimate extracted | 2 studies · 911 participants | Moderate Downgraded: imprecision |
Health‐related quality of life: change in SGRQ total score Scale: 0 to 100 (lower is better) All participants Mepolizumab 100 mg vs placebo | no estimate extracted | 2 studies · 1285 participants | Moderate Downgraded: imprecision |
Mepolizumab 300 mg compared with placebo for chronic obstructive pulmonary disease
Population: individuals with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rate of moderate or severe exacerbations Eosinophilic phenotype Mepolizumab 300 mg vs placebo | Rate ratio 0.86 [0.7, 1.06] | 1 study · 451 participants | Moderate Downgraded: imprecision |
Time to first moderate or severe exacerbation Eosinophilic phenotype Mepolizumab 300 mg vs placebo | Hazard ratio 0.77 [0.6, 0.99] | 1 study · 451 participants | Moderate Downgraded: imprecision |
Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype Mepolizumab 300 mg vs placebo | Rate ratio 0.83 [0.51, 1.35] | 1 study · 451 participants | Moderate Downgraded: imprecision |
Serious adverse events Mepolizumab 300 mg vs placebo | Odds ratio 0.84 [0.56, 1.27] | 1 study · 451 participants | Moderate Downgraded: imprecision |
Health‐related quality of life: change in SGRQ total score Scale: 0 to 100 (lower is better) Eosinophilic phenotype Mepolizumab 300 mg vs placebo | no estimate extracted | 1 study · 451 participants | Moderate Downgraded: imprecision |
Mepolizumab 750 mg compared with placebo for chronic obstructive pulmonary disease
Population: individuals with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an exacerbation within 6 months Mepolizumab 750 mg vs placebo | Odds ratio 0.43 [0.06, 2.97] | 1 study · 18 participants | Low Downgraded: imprecision |
Number of participants experiencing an exacerbation in 4‐month Mepolizumab 750 mg vs placebo | Odds ratio 9 [0.75, 108.31] | 1 study · 18 participants | Low Downgraded: imprecision |
Serious adverse events Mepolizumab 750 mg vs placebo | Odds ratio 3 [0.22, 40.93] | 1 study · 18 participants | Low Downgraded: imprecision |
Heath‐related quality of life (CRQ at 6 months) Mepolizumab 750 mg vs placebo | no estimate extracted | 1 study · 18 participants | Low Downgraded: imprecision |
Lung function (FEV₁) (litres post‐bronchodilator) at 6 months Mepolizumab 750 mg vs placebo | no estimate extracted | 1 study · 18 participants | Low Downgraded: imprecision |
Benralizumab 10 mg compared with placebo for chronic obstructive pulmonary disease
Population: individuals with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL Benralizumab 10 mg vs placebo | Rate ratio 0.85 [0.71, 1.02] | 1 study · 765 participants | Moderate Downgraded: imprecision |
Rate of moderate or severe exacerbations Eosinophils < 220/μL Benralizumab 10 mg vs placebo | Rate ratio 1.04 [0.82, 1.32] | 1 study · 365 participants | Moderate Downgraded: imprecision |
Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL Benralizumab 10 mg vs placebo | Rate ratio 0.68 [0.49, 0.94] | 1 study · 765 participants | Moderate Downgraded: imprecision |
Serious adverse events Benralizumab 10 mg vs placebo | Odds ratio 0.9 [0.69, 1.17] | 1 study · 1129 participants | Moderate Downgraded: imprecision |
Heath‐related quality of life, change in SGRQ total score Scale: 0 to 100 (lower is better) Eosinophils ≥ 220/μL Benralizumab 10 mg vs placebo | no estimate extracted | 1 study · 680 participants | Moderate Downgraded: imprecision |
Lung function (FEV₁) Eosinophils ≥ 220/μL Benralizumab 10 mg vs placebo | no estimate extracted | 1 study · 669 participants | Moderate Downgraded: imprecision |
Benralizumab 30 mg compared with placebo for chronic obstructive pulmonary disease
Population: individuals with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL Benralizumab 30 mg vs placebo | Rate ratio 1 [0.89, 1.13] | 2 studies · 1523 participants | Moderate Downgraded: imprecision |
Rate of moderate or severe exacerbations Eosinophils < 220/μL Benralizumab 30 mg vs placebo | Rate ratio 1.07 [0.91, 1.27] | 2 studies · 711 participants | Moderate Downgraded: imprecision |
Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL Benralizumab 30 mg vs placebo | Rate ratio 0.96 [0.75, 1.22] | 2 studies · 1523 participants | Moderate Downgraded: imprecision |
Serious adverse events Benralizumab 30 mg vs placebo | Odds ratio 0.98 [0.81, 1.17] | 2 studies · 2235 participants | Moderate Downgraded: imprecision |
Heath‐related quality of life, change in SGRQ total score Scale: 0 to 100 (lower is better) Eosinophils ≥ 220/μL Benralizumab 30 mg vs placebo | no estimate extracted | 2 studies · 1333 participants | Moderate Downgraded: imprecision |
Lung function (FEV₁) Eosinophils ≥ 220/μL Benralizumab 30 mg vs placebo | no estimate extracted | 2 studies · 1312 participants | Moderate Downgraded: imprecision |
Benralizumab 100 mg compared with placebo for chronic obstructive pulmonary disease
Population: individuals with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rate of moderate or severe exacerbations Benralizumab 100 mg vs placebo | Rate ratio 0.94 [0.85, 1.03] | 3 studies · 2314 participants | Moderate Downgraded: imprecision |
Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL Benralizumab 100 mg vs placebo | Rate ratio 0.88 [0.78, 1] | 2 studies · 1512 participants | Moderate Downgraded: imprecision |
Rate of moderate or severe exacerbations Eosinophils < 220/μL Benralizumab 100 mg vs placebo | Rate ratio 1.02 [0.87, 1.2] | 2 studies · 720 participants | Moderate Downgraded: imprecision |
Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL Benralizumab 100 mg vs placebo | Rate ratio 0.63 [0.49, 0.81] | 2 studies · 1512 participants | High |
Serious adverse events Benralizumab 100 mg vs placebo | Odds ratio 0.9 [0.75, 1.08] | 3 studies · 2333 participants | Moderate Downgraded: imprecision |
Heath‐related quality of life, change in SGRQ total score Scale: 0 to 100 (lower is better) Benralizumab 100 mg vs placebo | no estimate extracted | 3 studies · 1433 participants | High |
Heath‐related quality of life, change in SGRQ total score Scale: 0 to 100 (lower is better) Eosinophils ≥ 220/μL Benralizumab 100 mg vs placebo | no estimate extracted | 2 studies · 1351 participants | High |
Lung function (FEV₁) Benralizumab 100 mg vs placebo | no estimate extracted | 3 studies · 1425 participants | High |
Lung function (FEV₁) Eosinophils ≥ 220/μL Benralizumab 100 mg vs placebo | no estimate extracted | 2 studies · 1334 participants | Moderate Downgraded: imprecision |